Cost sharing, adherence, and health outcomes in patients with diabetes

American Journal of Managed Care

Volumn 16, Issue 8, 2010, Pages 589-600

  Gibson, Teresa B ^a   Song, Xue ^a   Alemayehu, Berhanu ^b   Wang, Sara S ^a   Waddell, Jessica L ^a   Bouchard, Jonathan R ^c   Forma, Felicia ^d  

^a THOMSON REUTERS   (United States)

^b ASTRAZENECA   (United Kingdom)

^c NOVO NORDISK INC   (United States)

^d SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA GLUCOSIDASE INHIBITOR; BIGUANIDE; INSULIN; MEGLITINIDE; SULFONYLUREA;

ABSENTEEISM; ACUTE HEART INFARCTION; ADULT; AMPUTATION; ARTICLE; CEREBROVASCULAR DISEASE; CROSS-SECTIONAL STUDY; EMERGENCY WARD; FEMALE; HEALTH CARE COST; HEALTH CARE POLICY; HUMAN; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL SERVICE; NEUROPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; PRODUCTIVITY; RETINOPATHY; RETROSPECTIVE STUDY; TREATMENT OUTCOME; ULCER; WORK DISABILITY; WORKPLACE;

CONFIDENCE INTERVALS; COST SHARING; CROSS-SECTIONAL STUDIES; DATABASES, FACTUAL; DIABETES MELLITUS, TYPE 2; EFFICIENCY; FEMALE; HEALTH STATUS INDICATORS; HUMANS; HYPOGLYCEMIC AGENTS; INPATIENTS; LOGISTIC MODELS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; MODELS, ECONOMIC; MULTIVARIATE ANALYSIS; ODDS RATIO; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME; UNITED STATES; WORKPLACE;

EID: 77956123264     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Centers for Disease Control and Prevention. National Diabetes Fact Sheet 2007. http://www.cdc.gov/diabetes/pubs/pdf/ndfs-2007.pdf. Accessed February 28, 2010.
2. Odegard PS, Capoccia K. Medication taking and diabetes: a systematic review of the literature. Diabetes Educ. 2007;33(6):1014-1029.
3. Gibson TB, Ozminkowski RJ, Goetzel RZ.The effects of prescription drug cost sharing: a review of the evidence. Am J Manag Care. 2005;11(11):730-740.
4. Goldman DP, Joyce GF, Zheng Y. Prescription drug cost sharing: associations with medication and medical utilization and spending and health. JAMA. 2007;298(1):61-69. (Pubitemid 47026771)
5. Encinosa W, Bemard D, Dor A. Does Prescription Drug Adherence Reduce Hospitalizations and Costs? Cambridge, MA: National Bureau of Economic Research; January 2010:1-35. Working Paper No. 15691. http://www.nber.org/papers/w15691.
6. Sokol MC, McGuigan KA, Verbrugge RR, Epstein RS. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care. 2005;43(6):521-530.
7. Ho PM, Rumsfeld JS, Masoudi FA, et al. Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus. Arch Intern Med. 2006;166(17):1836-1841.
8. Chernew M, Gibson TB, Yu-Isenberg K, Sokol MC, Rosen AB, Fendrick AM. Effects of increased patient cost sharing on socioeconomic disparities in health care. J Gen Intern Med. 2008;23(8):1131-1136.
9. Hunt J, Rozenfeld Y, Shenolikar R. Effect of patient medication cost share on adherence and glycemic control: higher cost sharing decreases adherence to oral diabetes drugs and worsens glucose levels. Manag Care. 2009;18(7):47-53.
10. Karve S, Cleves MA, Helm M, Hudson TJ, West DS, Martin BC. An empirical basis for standardizing adherence measures derived from administrative claims data among diabetic patients. Med Care. 2008;46(11):1125-1133.
11. Kleinman NL, Schaneman JL, Lynch WD. The association of insulin medication possession ratio, use of insulin glargine, and health benefit costs in employees and spouses with type 2 diabetes. J Occup Environ Med. 2008;50(12):1386-1393.
12. Choudhry NK, Shrank WH, Levin RL, et al. Measuring concurrent adherence to multiple related medications. Am J Manag Care. 2009;15(7):457-464.
13. Chemew M, Gibson TB. Cost sharing and HEDIS performance. Med Care Res Rev. 2008;65(6):713-728.
14. Gaynor M, Li J, Vogt WB. Is Drug Coverage a Free Lunch? Cross-Price Elasticities and the Design of Prescription Drug Benefits. Cambridge, MA: National Bureau of Economic Research; December 2006:1-39. Working Paper No. 12758. http://www.nber.org/papers/w12758. Accessed May 26, 2010.
15. Mark TL, GibsonTB, McGuigan KA. The effects of antihypertensive step-therapy protocols on pharmaceutical and medical utilization and expenditures. Am J Manag Care. 2009;15(2):123-131.
16. Joyce GF, Escarce JJ, Solomon MD, Goldman DP. Employer drug benefit plans and spending on prescription drugs. JAMA. 2002;288(14):1733-1739.
17. Colombi AM, Yu-Isenberg K, Priest J. The effects of health plan copayments on adherence to oral diabetes medication and health resource utilization. J Occup Environ Med. 2008;50(5):535-541. (Pubitemid 351677636)
18. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45(6):613-619.
19. Rozenfeld Y, Hunt JS, Plauschinat C, Wong KS. Oral antidiabetic medication adherence and glycemic control in managed care. Am J Manag Care. 2008;14(2):71-75. (Pubitemid 351312089)
20. Terza JV, Basu A, Rathouz PJ. Two-stage residual inclusion estimation: addressing endogeneity in health econometric modeling. J Health Econ. 2008;27(3):531-543.
21. Schectman JM, Nadkami MM, Voss JD. The association between diabetes metabolic control and drug adherence in an indigent population. Diabetes Care. 2002;25(6):1015-1021.
22. Lee WC, Balu S, Cobden D, Joshi AV, Pashos CL. Prevalence and economic consequences of medication adherence in diabetes: a systematic literature review. Manag Care Interface. 2006;19(7):31-41. (Pubitemid 44148014)
23. Lau DT, Nau DP. Oral antihyperglycemic medication nonadherence and subsequent hospitalization among individuals with type 2 diabetes. Diabetes Care. 2004;27(9):2149-2153.